Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07094516 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 407
- Enrollment target
- 20
- Study locations
NCT07094516: Recruiting Phase 2 study of Alzheimers Disease, sponsored by Novartis Pharmaceuticals.
NCT07094516 is a Phase 2 study of Alzheimers Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 407 participants, below the 3,923-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07094516, a Phase 2 study of Alzheimers Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 407 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
Primary Outcome
The CDR is a measure of cognition and function, widely used in clinical research in AD. The scale assesses six domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care. Based on in-depth semi-structured interview, each domain is assigned a score, which is summed to obtain the Sum of Boxes (SB) score, ranging from 0 to 18 with higher scores indicating worse condition
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL VHB937
Study Locations (20)
Florida
- Jem Research Institute - Atlantis
- Visionary Investigators Network - Aventura
- K2 Medical Research LLC - Maitland
- K2 Medical Research LLC - Maitland
- Renstar Medical Research - Ocala
- Charter Research The Villages - The Villages
- Alzheimers Research Treatment Ctr - Wellington
- Alzheimers Research Treatment Ctr - Wellington
- Conquest Research - Winter Park
California
- University of California San Diego - La Jolla
- University of California at Los Angeles - Los Angeles
Arizona
- Banner Alzheimers Institute - Phoenix
Hawaii
- Hawaii Pacific Neuroscience LLC - Honolulu
Kansas
- University of Kansas Hospital - Fairway
Massachusetts
- ActivMed Practices and Research - Methuen
Missouri
- Citizens Memorial Hospital Neurology CLinic - Bolivar
North Carolina
- UNC Hosp Invest Drug Serv Pharm - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
What NCT07094516 shows while recruiting
NCT07094516 is an interventional study that assigns participants to a tested intervention. The registered 407 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07094516 names 20 study sites across 11 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07094516 about?
NCT07094516 is a clinical study titled "A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease". This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
What is the current status of trial NCT07094516?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 407 participants. The study started on 2025-08-07. Estimated completion is 2030-12-31.
What conditions does trial NCT07094516 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT07094516?
The interventions under investigation include: Placebo (OTHER), VHB937 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07094516?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07094516 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Hawaii, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07094516's enrollment target sits among peer trials
407 33rd of 147 higher than 115 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI